RT @Cochrane_Child: New #CochraneEvidence: Potentiators (specific therapies for class III and IV mutations) for #cysticfibrosis | https://t…
315 followers
47 followers
RT @ATS_BSHSR: Potentiators (specific therapies for class III and IV mutations) for #cysticfibrosis #CF #lung https://t.co/cuWaYVvil5 https…
1,950 followers
Potentiators (specific therapies for class III and IV mutations) for #cysticfibrosis #CF #lung https://t.co/cuWaYVvil5 https://t.co/skZ6rzeNQH
4,885 followers
New #CochraneEvidence: Potentiators (specific therapies for class III and IV mutations) for #cysticfibrosis | https://t.co/kb1qeBJxZE #childhealth https://t.co/QzgyRhDDrz
37 followers
RT @CFAware: Ivacaftor (marketed as Kalydeco®), a new specific therapy for cystic fibrosis | Cochrane https://t.co/D9ayRj0UAl
190 followers
Ivacaftor (marketed as Kalydeco®), a new specific therapy for cystic fibrosis https://t.co/Xp7QjiH9Ex